EU-FUND INVESTMENT ACTION PROGRAMME 2014-2020

Presently, “Froceth”, JSC and the National Institute of Cancer are implementing the project “Medical products modulating the advanced therapy immune system for the treatment of cancer” that is co-funded with the support of the European Fund of Regional Development provided according to the Programme of Investment Actions of the EU-Funds 2014–2020.

During the project, it is planned to develop 3 autologous vaccines of dendritic cells where the immune response would be modulated by using exosomes for different cancer localizations:

● Anti-cancer autologous vaccine of dendritic cells for the treatment of glioblastoma;

● Anti-cancer autologous vaccine of dendritic cells for the treatment of melanoma;

● Anti-cancer autologous vaccine of dendritic cells for the treatment of lung cancer.

EU-FUND INVESTMENT ACTION PROGRAMME 2014-2020
Back